MANE Stock — Veradermics, Incorporated

Veradermics, Incorporated (MANE)

Updated October 16, 2026.

MANE is a Stock. Total return is 188.3% over the past 0.7 years, 176.2 points ahead of SPY at 12.1%.

Veradermics is a clinical-stage biopharmaceutical company developing novel treatments for dermatologic and aesthetic conditions, including oral and topical therapies for pattern hair loss, alopecia areata, common warts, molluscum contagiosum, and atopic dermatitis. As an early-stage company, it does not currently distribute to shareholders. The company targets healthcare providers and clinicians treating both adult and pediatric dermatologic conditions.

MANE performance versus SPY

Price and return data through 2026-10-16.

Total return is 188.3% over the past 0.7 years, 176.2 points ahead of SPY at 12.1%.

MANE key facts

Asset type

Stock

Asset class

Equity

Inception date

02/04/2026

Distribution frequency

None

Last close

$108.82 (as of 2026-10-16)

Market cap

$4,546,514,400

Average volume

672880.0

Payout ratio

0.0%

EPS

$-4.14

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

Who may consider MANE — and who may not

It is a weaker fit for investors who need monthly cash flow (MANE does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on MANE

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions